Browse the corpus

This activity aligns with the American Board of Obesity Medicine's content blueprint for the Obesity Medicine board exam. Specifically, this course covers the material in the "A" duties of a physician (A: Evaluating, Examining, and Diagnosing) and the necessary task 12 in the outline (ie, A:12 in the exam blueprint): Diagnose genetic or syndromic causes of obesity. Genetic and syndromic causes of obesity represent a clinically significant subset of severe obesity that is often underrecognized in practice. These include monogenic disorders, such as leptin deficiency and melanocortin 4 receptor deficiency, as well as syndromic conditions like Prader-Willi syndrome and Bardet-Biedl syndrome. Patients frequently present with early-onset obesity, hyperphagia, dysmorphic features, or developmental delays that are easily overlooked during standard assessments. Delayed recognition leads to missed opportunities for early intervention and access to precision therapies. Advances in molecular diagnostics now allow more accurate characterization of these disorders. Still, many clinicians lack familiarity with the key red flags, testing strategies, and therapeutic pathways needed for timely diagnosis and management. Early recognition of genetic etiologies is essential for guiding appropriate care and improving long-term outcomes. Participants in this activity learn systematic approaches for identifying genetic and syndromic obesity, including recognizing early clinical indicators, applying diagnostic algorithms, and using evidence-based genetic testing. Clinicians enhance competence in interpreting complex presentations, initiating referrals, and integrating therapeutic advances, including targeted therapies and coordinated behavioral strategies. Interactive case studies reinforce clinical reasoning and practical decision-making. The course also emphasizes interprofessional collaboration, illustrating how coordinated efforts among clinicians, geneticists, dietitians, endocrinologists, and mental health specialists enhance diagnostic accuracy and patient-centered care. Objectives: Implement standardized screening protocols incorporating validated questionnaires, growth monitoring, and developmental assessments across the lifespan. Interpret genetic testing results to diagnose patients with suspected monogenic or syndromic obesity.

Participants in this activity learn systematic approaches for identifying genetic and syndromic obesity, including recognizing early clinical indicators, applying diagnostic algorithms, and using evidence-based genetic testing. Clinicians enhance competence in interpreting complex presentations, initiating referrals, and integrating therapeutic advances, including targeted therapies and coordinated behavioral strategies. Interactive case studies reinforce clinical reasoning and practical decision-making. The course also emphasizes interprofessional collaboration, illustrating how coordinated efforts among clinicians, geneticists, dietitians, endocrinologists, and mental health specialists enhance diagnostic accuracy and patient-centered care. Objectives: Implement standardized screening protocols incorporating validated questionnaires, growth monitoring, and developmental assessments across the lifespan. Interpret genetic testing results to diagnose patients with suspected monogenic or syndromic obesity. Evaluate patients to determine if they are appropriate candidates for targeted therapies based on their genetic diagnoses. Coordinate interprofessional team management involving endocrinology, genetics, nutrition, and behavioral health specialists to optimize comprehensive care for patients with genetic obesity syndromes. Access free multiple choice questions on this topic.

Genetic and epigenetic factors play a vital role in the pathogenesis of obesity. Obesity affects over 650 million adults worldwide, with most attributed to polygenic factors combined with environmental influences. While monogenic and syndromic forms of obesity are rare, recognizing them is essential, as accurate diagnosis directly informs targeted treatment strategies and optimizes patient outcomes. These genetic forms of obesity typically present with severe, early-onset obesity accompanied by distinctive clinical features that differentiate them from typical polygenic obesity. The most studied monogenic form of obesity involves the leptin-melanocortin pathway, the central regulatory mechanism for energy homeostasis and appetite control. Monogenic obesity affects approximately 1% to 5% of individuals with severe, early-onset obesity, defined as obesity that begins before age 5 in children whose body mass index (BMI) is greater than the 95th percentile for age and sex. The most common monogenic causes involve disruptions in the leptin-melanocortin pathway, including leptin deficiency, leptin receptor (LEPR) deficiency, melanocortin-4 receptor (MC4R) deficiency, and proopiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiencies.[1] Early recognition of genetic and syndromic causes of obesity is crucial for implementing appropriate interventions, providing genetic counseling, and optimizing long-term outcomes. The development of targeted therapies, eg, setmelanotide and diazoxide choline extended-release tablets, VYKAT XR, represents significant advances in the treatment of these previously difficult-to-manage conditions. Epidemiology of Genetic Obesity Twin studies have estimated the heritability of obesity to be between 40% and 70%. Over 100 genetic loci contribute to typical obesity, as identified through genome-wide association studies (GWAS). However, the identified loci explain only a small fraction of the heritability, a phenomenon known as the "missing heritability" problem. Possible explanations for this missing heritability include rare variants with large effect sizes, gene-gene interactions, and epigenetic modifications not captured in traditional GWAS studies. Obesity Epigenetics

Twin studies have estimated the heritability of obesity to be between 40% and 70%. Over 100 genetic loci contribute to typical obesity, as identified through genome-wide association studies (GWAS). However, the identified loci explain only a small fraction of the heritability, a phenomenon known as the "missing heritability" problem. Possible explanations for this missing heritability include rare variants with large effect sizes, gene-gene interactions, and epigenetic modifications not captured in traditional GWAS studies. Obesity Epigenetics Epigenetic modifications, eg, deoxyribonucleic acid (DNA) methylation and histone modifications, influence gene expression without altering the underlying DNA sequence. Environmental factors, eg, maternal nutrition during pregnancy, can influence these modifications. For example, maternal undernutrition during pregnancy has been linked to an increased risk of obesity in offspring through epigenetic mechanisms that affect genes involved in metabolism and appetite regulation. Red Flags for Genetic Obesity Clinicians should request a referral for a genetic evaluation if any of the following red flag indicators are present in patients with obesity: Severe obesity onset before age 5 years Hyperphagia with food-seeking behaviors Obesity accompanied by developmental delays Obesity with distinctive dysmorphic features A family history of severe early-onset obesity Obesity and endocrine abnormalities (eg, hypogonadism and growth hormone deficiency) Obesity and vision problems or polydactyly A failure to respond to standard weight management interventions Genetic Obesity Pathophysiology Overview

Obesity accompanied by developmental delays Obesity with distinctive dysmorphic features A family history of severe early-onset obesity Obesity and endocrine abnormalities (eg, hypogonadism and growth hormone deficiency) Obesity and vision problems or polydactyly A failure to respond to standard weight management interventions Genetic Obesity Pathophysiology Overview The pathophysiology of genetic obesity primarily involves disruption of the hypothalamic leptin-melanocortin pathway, which serves as the central regulatory system for energy homeostasis. This pathway begins with leptin, an adipocyte-derived hormone that signals satiety to the hypothalamus.[2] Please refer to the StatPearls companion resource, "Physiology, Leptin", for further information on leptin physiology. Within the hypothalamus, leptin signaling activates proopiomelanocortin (POMC) neurons, which produce α-melanocyte-stimulating hormone (α-MSH) through cleavage by proprotein convertase subtilisin/kexin type 1 (PCSK1). Melanocortin-4 receptors (MC4R) bind to α-MSH on downstream neurons, decreasing food intake and increasing energy expenditure.[3] Disruption at any point in this pathway results in severe obesity characterized by hyperphagia, reduced satiety, and decreased energy expenditure. The severity of the phenotype often correlates with the degree of pathway disruption, with complete deficiencies producing more severe obesity than partial deficiencies (see Table 1).[4] Table Table 1. Clinical Features of Genetic Obesity Syndromes. Table Table Pause and Reflect.

Caring for individuals with genetic obesity syndromes requires a coordinated interprofessional team approach, as these conditions involve multiple organ systems and require ongoing, specialized interventions. Collaboration among healthcare disciplines supports comprehensive, patient-centered care, improving short-term and long-term outcomes. Primary care physicians and advanced practitioners are responsible for recognizing red flag indicators, initiating diagnostic testing, and making appropriate referrals to genetics, endocrinology, and neurology specialists. Endocrinologists play a central role in managing all genetic obesity syndromes through hormone replacement therapy, metabolic regulation, and the administration of targeted therapies. Geneticists contribute by confirming diagnoses, offering genetic counseling, and assisting families with reproductive planning. Ophthalmologists manage visual complications through regular monitoring and providing low-vision services in conditions such as BBS and Alström syndrome. Cardiologists monitor cardiovascular health in patients with BBS and Alström syndrome, while nephrologists provide renal monitoring and management due to the high risk of kidney involvement. Pulmonologists conduct sleep evaluations and deliver ventilatory support in syndromes with respiratory complications, eg, PWS and ROHHAD syndrome. Nutrition specialists and registered dietitians support patients and their families through tailored dietary interventions and feeding therapy, particularly crucial during the early stages of development. Behavioral health professionals address hyperphagia and associated behavioral challenges through structured interventions, particularly in individuals with PWS, BBS, and MC4R deficiency. Nurses and pharmacists play vital roles in caring for patients with genetic obesity syndromes. Nurses provide education on the condition and treatment plan, coordinate care among specialists, monitor growth and comorbidities, and support adherence to nutrition, activity, and medication regimens. Pharmacists optimize medication management by reviewing prescriptions for efficacy, potential interactions, and side effects, educating patients and their families on proper use, and monitoring outcomes.

Nutrition specialists and registered dietitians support patients and their families through tailored dietary interventions and feeding therapy, particularly crucial during the early stages of development. Behavioral health professionals address hyperphagia and associated behavioral challenges through structured interventions, particularly in individuals with PWS, BBS, and MC4R deficiency. Nurses and pharmacists play vital roles in caring for patients with genetic obesity syndromes. Nurses provide education on the condition and treatment plan, coordinate care among specialists, monitor growth and comorbidities, and support adherence to nutrition, activity, and medication regimens. Pharmacists optimize medication management by reviewing prescriptions for efficacy, potential interactions, and side effects, educating patients and their families on proper use, and monitoring outcomes. This coordinated interprofessional model ensures the team focuses on each patient's complex needs. Successful care implementation requires ongoing communication, shared decision-making with families, and the integration of genetic counseling. The healthcare team can collaborate to coordinate diagnostic evaluations, develop individualized treatment plans, and improve long-term outcomes for patients and their families.